Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. - Université de Bretagne Occidentale Access content directly
Journal Articles Thrombosis and Haemostasis Year : 2003

Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.

Abstract

C-reactive protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal estrogen replacement therapy (ERT) increases CRP levels, but the effect of transdermal ERT is not well documented. CRP, interleukine-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were evaluated in a randomised study of 196 healthy postmenopausal women, who were allocated to receive continuous oral estradiol-1beta, (n=63) or transdermal estradiol-1beta, (n=68) both combined with micronised progesterone, or place-bo (n=65). Oral estrogen increased CRP levels compared with both placebo (p=0.010) and transdermal estrogen (p=0.004) at 6 months. There was no significant effect of transdermal estrogen on CRP levels compared with placebo (p=0.997). No significant difference was found in the median changes for IL-6 and TNF-alpha between the three treatment groups. In conclusion, transdermal estrogen has no significant effect on CRP levels at 6 months, but CRP concentrations increased significantly with oral estrogen although no changes in cytokine levels were detected. The clinical relevance of these effects remains to be determined.
No file

Dates and versions

hal-00722269 , version 1 (01-08-2012)

Identifiers

Cite

Karine Lacut, Emmanuel Oger, Grégoire Le Gal, Marie-Thérèse Blouch, Jean-François Abgrall, et al.. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.. Thrombosis and Haemostasis, 2003, 90 (1), pp.124-31. ⟨10.1267/THRO03010124⟩. ⟨hal-00722269⟩
76 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More